The aim of this study is to evaluate the efficacy and safety of pazopanib compared with
placebo in patients with T < or = 5 cm, N0 (stage I according to TNM 2009) completely
resected NSCLC.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique